CELLINK Q5 2020 Results and MatTek Acquisition
Strong organic growth and important strategic
acquisition under continued challenging conditions
CELLINK
"LIFE SCIENCES
94
KSEK
Net sales*
Net sales Laboratory Solutions*
Net sales Industrial Solutions*
Gross profit
Gross margin, %
Sep-Dec 2020
239,216
Sep-Dec 2019
50,189
Sep 2019-Dec 2020
233
Sep 2018-Dec 2019
416,009
155,646
87,040
263,833
152,176
174,368
35,073
298,633
73%
70%
72%
110,496
71%
Operating profit before depreciation and amortization
(EBITDA)
40,414
-15,567
816
-12,216
Operating margin before depreciation and amortization
(EBITDA), %
16.9%
-31.0%
0.2%
-7.8%
Operating profit (EBIT)
14,161
-22,508
-51,927
-26,262
Operating margin (EBIT), %
5.9%
-44.8%
-12.5%
-16.9%
Profit for the period
13,219
-18,895
-48,994
-18,314
Diluted earnings per share, SEK**
0.26
-0.48
-1.10
Net debt(-)/Net cash(+)
Cash flow from operating activities
Average number of shares**, ***
Number of shares at the end of the period**
Share price on closing day, SEK**
Market capitalization on closing day, MSEK
Number of employees at the end of the period
755,738
-7,584
52,951,049
68,840
-13,847
39,374,416
51,601,285
38,984,776
755,738
-79,400
44,888,273
51,601,285
-0.51
68,840
-29,665
36,024,097
38,984,776
234.5
83.5
234.5
12,101
3,255
396
183
12,101
396
83.5
3,255
183
*
Segment created September 2020, see note 3 in latest report
** CELLINK conducted a 4:1 split on January 10, 2020. Comparison periods have been restated for correct comparison.
For definitions, see latest report on www.cellink.com/investors
*** Average number of shares including potential ordinary shares.
CELLINK 2021, All rights reserved.View entire presentation